365 related articles for article (PubMed ID: 27640936)
1. Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction.
Foster TL; Wilson H; Iyer SS; Coss K; Doores K; Smith S; Kellam P; Finzi A; Borrow P; Hahn BH; Neil SJD
Cell Host Microbe; 2016 Oct; 20(4):429-442. PubMed ID: 27640936
[TBL] [Abstract][Full Text] [Related]
2. Functional Heterogeneity of Mammalian IFITM Proteins against HIV-1.
Marziali F; Delpeuch M; Kumar A; Appourchaux R; Dufloo J; Tartour K; Etienne L; Cimarelli A
J Virol; 2021 Aug; 95(18):e0043921. PubMed ID: 34160255
[TBL] [Abstract][Full Text] [Related]
3. The Inhibition of HIV-1 Entry Imposed by Interferon Inducible Transmembrane Proteins Is Independent of Co-Receptor Usage.
Yu J; Liu SL
Viruses; 2018 Aug; 10(8):. PubMed ID: 30087232
[TBL] [Abstract][Full Text] [Related]
4. The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity.
Wang Y; Pan Q; Ding S; Wang Z; Yu J; Finzi A; Liu SL; Liang C
J Virol; 2017 Apr; 91(7):. PubMed ID: 28100616
[TBL] [Abstract][Full Text] [Related]
5. IFITM Proteins That Restrict the Early Stages of Respiratory Virus Infection Do Not Influence Late-Stage Replication.
Meischel T; Fritzlar S; Villalon-Letelier F; Tessema MB; Brooks AG; Reading PC; Londrigan SL
J Virol; 2021 Sep; 95(20):e0083721. PubMed ID: 34319159
[TBL] [Abstract][Full Text] [Related]
6. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity.
Tartour K; Appourchaux R; Gaillard J; Nguyen XN; Durand S; Turpin J; Beaumont E; Roch E; Berger G; Mahieux R; Brand D; Roingeard P; Cimarelli A
Retrovirology; 2014 Nov; 11():103. PubMed ID: 25422070
[TBL] [Abstract][Full Text] [Related]
7. IFITM proteins: Understanding their diverse roles in viral infection, cancer, and immunity.
Gómez-Herranz M; Taylor J; Sloan RD
J Biol Chem; 2023 Jan; 299(1):102741. PubMed ID: 36435199
[TBL] [Abstract][Full Text] [Related]
8. Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV.
Wilkins J; Zheng YM; Yu J; Liang C; Liu SL
PLoS One; 2016; 11(6):e0156739. PubMed ID: 27257969
[TBL] [Abstract][Full Text] [Related]
9. HIV envelope tail truncation confers resistance to SERINC5 restriction.
Haider T; Snetkov X; Jolly C
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34001619
[TBL] [Abstract][Full Text] [Related]
10. Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs.
Tartour K; Nguyen XN; Appourchaux R; Assil S; Barateau V; Bloyet LM; Burlaud Gaillard J; Confort MP; Escudero-Perez B; Gruffat H; Hong SS; Moroso M; Reynard O; Reynard S; Decembre E; Ftaich N; Rossi A; Wu N; Arnaud F; Baize S; Dreux M; Gerlier D; Paranhos-Baccala G; Volchkov V; Roingeard P; Cimarelli A
PLoS Pathog; 2017 Sep; 13(9):e1006610. PubMed ID: 28957419
[TBL] [Abstract][Full Text] [Related]
11. The Envelope Gene of Transmitted HIV-1 Resists a Late Interferon Gamma-Induced Block.
Rihn SJ; Foster TL; Busnadiego I; Aziz MA; Hughes J; Neil SJD; Wilson SJ
J Virol; 2017 Apr; 91(7):. PubMed ID: 28100611
[TBL] [Abstract][Full Text] [Related]
12. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
13. Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.
Zhao X; Sehgal M; Hou Z; Cheng J; Shu S; Wu S; Guo F; Le Marchand SJ; Lin H; Chang J; Guo JT
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263263
[TBL] [Abstract][Full Text] [Related]
14. pH Optimum of Hemagglutinin-Mediated Membrane Fusion Determines Sensitivity of Influenza A Viruses to the Interferon-Induced Antiviral State and IFITMs.
Gerlach T; Hensen L; Matrosovich T; Bergmann J; Winkler M; Peteranderl C; Klenk HD; Weber F; Herold S; Pöhlmann S; Matrosovich M
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356532
[TBL] [Abstract][Full Text] [Related]
15. IFITM1 and IFITM3 Proteins Inhibit the Infectivity of Progeny HIV-1 without Disrupting Envelope Glycoprotein Clusters.
Verma S; Chen YC; Marin M; Gillespie SE; Melikyan GB
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140631
[TBL] [Abstract][Full Text] [Related]
16. IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.
Yu J; Li M; Wilkins J; Ding S; Swartz TH; Esposito AM; Zheng YM; Freed EO; Liang C; Chen BK; Liu SL
Cell Rep; 2015 Oct; 13(1):145-156. PubMed ID: 26387945
[TBL] [Abstract][Full Text] [Related]
17. Role of Viral Envelope Proteins in Determining Susceptibility of Viruses to IFITM Proteins.
Marceau T; Braibant M
Viruses; 2024 Feb; 16(2):. PubMed ID: 38400030
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.
Wilen CB; Parrish NF; Pfaff JM; Decker JM; Henning EA; Haim H; Petersen JE; Wojcechowskyj JA; Sodroski J; Haynes BF; Montefiori DC; Tilton JC; Shaw GM; Hahn BH; Doms RW
J Virol; 2011 Sep; 85(17):8514-27. PubMed ID: 21715507
[TBL] [Abstract][Full Text] [Related]
19. Virion Background and Efficiency of Virion Incorporation Determine Susceptibility of Simian Immunodeficiency Virus Env-Driven Viral Entry to Inhibition by IFITM Proteins.
Wrensch F; Hoffmann M; Gärtner S; Nehlmeier I; Winkler M; Pöhlmann S
J Virol; 2017 Jan; 91(2):. PubMed ID: 27807233
[TBL] [Abstract][Full Text] [Related]
20. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread.
Compton AA; Bruel T; Porrot F; Mallet A; Sachse M; Euvrard M; Liang C; Casartelli N; Schwartz O
Cell Host Microbe; 2014 Dec; 16(6):736-47. PubMed ID: 25464829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
